ATE372770T1 - Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten - Google Patents

Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten

Info

Publication number
ATE372770T1
ATE372770T1 AT03766118T AT03766118T ATE372770T1 AT E372770 T1 ATE372770 T1 AT E372770T1 AT 03766118 T AT03766118 T AT 03766118T AT 03766118 T AT03766118 T AT 03766118T AT E372770 T1 ATE372770 T1 AT E372770T1
Authority
AT
Austria
Prior art keywords
treatment
diseases
respond
compounds useful
angiogenic therapy
Prior art date
Application number
AT03766118T
Other languages
English (en)
Inventor
Jens Lichtenberg
Palle Christophersen
Bjarne Dahl
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE372770T1 publication Critical patent/ATE372770T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT03766118T 2002-08-01 2003-07-31 Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten ATE372770T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200201165 2002-08-01
DKPA200201839 2002-11-28
DKPA200300371 2003-03-11

Publications (1)

Publication Number Publication Date
ATE372770T1 true ATE372770T1 (de) 2007-09-15

Family

ID=31498946

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766118T ATE372770T1 (de) 2002-08-01 2003-07-31 Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten

Country Status (17)

Country Link
US (1) US20060058395A1 (de)
EP (1) EP1526851B1 (de)
JP (1) JP2005537336A (de)
KR (1) KR20050026091A (de)
CN (1) CN1671378A (de)
AT (1) ATE372770T1 (de)
AU (1) AU2003260280A1 (de)
BR (1) BR0312929A (de)
CA (1) CA2493253A1 (de)
DE (1) DE60316297T2 (de)
IL (1) IL166040A0 (de)
IS (1) IS7723A (de)
MX (1) MXPA05001235A (de)
NO (1) NO20051074L (de)
NZ (1) NZ537809A (de)
PL (1) PL375318A1 (de)
WO (1) WO2004012733A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006527735A (ja) * 2003-06-17 2006-12-07 ノイロサーチ アクティーゼルスカブ ジフェニル尿素誘導体、及びクロライドチャネル遮断剤としてのそれらの使用
US7550499B2 (en) 2004-05-12 2009-06-23 Bristol-Myers Squibb Company Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
MX2007008434A (es) 2005-01-19 2007-07-25 Squibb Bristol Myers Co Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
EP1853286A2 (de) * 2005-02-08 2007-11-14 BMZ Diagnosis (2004) Ltd. Zusammensetzung zur behandlung von hauterkrankungen
ES2352796T3 (es) 2005-06-27 2011-02-23 Bristol-Myers Squibb Company Antagonistas cíclicos unidos a c del receptor p2y1 útiles en el tratamiento de afecciones trombóticas.
MX2007016501A (es) 2005-06-27 2008-03-06 Squibb Bristol Myers Co Antagonistas heterociclicos n-enlazados del receptor de p2y1, utiles en el tratamiento de condiciones tromboticas.
US7714002B2 (en) 2005-06-27 2010-05-11 Bristol-Myers Squibb Company Carbocycle and heterocycle antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
EP1896417B1 (de) 2005-06-27 2011-03-23 Bristol-Myers Squibb Company Lineare harnstoffmimetika-antagonisten des p2y1-rezeptors zur behandlung von thromboseleiden
US7960569B2 (en) 2006-10-17 2011-06-14 Bristol-Myers Squibb Company Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
US20110110958A1 (en) * 2007-09-11 2011-05-12 University Of Florida Research Foundation Compositions and methods for the treatment of neoplasia
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
SI3458052T1 (sl) 2016-05-17 2020-04-30 Scandion Oncology A/S Kombinirano zdravljenje raka
US20210251963A1 (en) * 2018-09-06 2021-08-19 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
IL132107A (en) * 1997-04-22 2004-09-27 Neurosearch As Substituted phenyl derivatives, their preparation and use
JP4607318B2 (ja) * 1997-12-22 2011-01-05 バイエル コーポレイション 対称および非対称置換ジフェニル尿素を用いるｒａｆキナーゼの阻害
CA2342626A1 (en) * 1998-10-22 2000-05-04 Neurosearch A/S Substituted phenyl derivatives, their preparation and use
CO5200760A1 (es) * 1999-06-16 2002-09-27 Smithkline Beecham Corp Antagonistas del receptor de la il-8 ceptor il-8
ATE543497T1 (de) * 2002-07-09 2012-02-15 Bristol Myers Squibb Co Substituierte heterozyklische derivate als mittel gegen diabetes und adipositas und verfahren

Also Published As

Publication number Publication date
CN1671378A (zh) 2005-09-21
EP1526851B1 (de) 2007-09-12
EP1526851A2 (de) 2005-05-04
WO2004012733A9 (en) 2005-03-10
KR20050026091A (ko) 2005-03-14
PL375318A1 (en) 2005-11-28
US20060058395A1 (en) 2006-03-16
DE60316297T2 (de) 2008-06-19
CA2493253A1 (en) 2004-02-12
JP2005537336A (ja) 2005-12-08
NZ537809A (en) 2007-05-31
MXPA05001235A (es) 2005-06-08
IL166040A0 (en) 2006-01-15
NO20051074L (no) 2005-04-29
AU2003260280A1 (en) 2004-02-23
WO2004012733A2 (en) 2004-02-12
WO2004012733A3 (en) 2004-03-18
IS7723A (is) 2005-03-01
DE60316297D1 (de) 2007-10-25
BR0312929A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
ATE372770T1 (de) Verbindungen nützlich in der behandlung von erkrankungen die auf anti-angiogenertherapie antworten
UA83194C2 (ru) Производные пиримидина и их применение как модуляторов св2
JO2534B1 (en) Pyrimidines carrying alternatives of sulfoximine as CDK and / or VEGF inhibitors and their production and use as pharmaceutical agents
ATE345329T1 (de) Pyridinderivate als modulatoren des cb2-rezeptors
PT1543011E (pt) Composto de tienopirrolilo e furanopirrolilo e sua utilizacao como ligandos do receptor h4 da histamina
NO20060230L (no) Nye aminobenzofenonforbindelser
BR0318383A (pt) derivados de pirazoloisoquinolina como inibidores de cinase
MY145077A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ATE430742T1 (de) Pyrimidinamine als angiogenesemodulatoren
DE602004022633D1 (de) 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
MY141867A (en) Substituted pyrimidines useful as protein kinase inhibitors
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
ATE313532T1 (de) Diaryl- und arylheteroarylharnstoffderivate als modulatoren des 5-ht2a-serotoninrezeptors, die sich zur prophylaxe und behandlung von damit im zusammenhang stehenden erkrankungen eignen
MX2023007998A (es) Regimenes de tratamiento con dexmedetomidina.
MX392158B (es) Anticuerpo que reconoce el peptido t14 de enzima acetilcolinesterasa (ache).
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
BR0312446A (pt) 2-heteroaril carboxamidas
DE60308699D1 (en) 2-phenylamino-4-trifluoromethyl-5-(benzyl- oder pyridin-4-ylmethyl)carbamoylpyrimidin-derivate als selektive cb2 cannabinoid-rezeptor modulatoren
ATE418550T1 (de) 8-(1-piperazinyl)-chinolinderivate und deren verwendung bei der behandlung von zns- erkrankungen
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα
GT200400231A (es) Compuestos de sulfoniltetrahidro-3h-benzo(e)indol-8-amina como ligandos de la 5-hidroxitriptamina-6.
DE60326742D1 (de) Piperazin und piperadin-derivate für die behandlung von neurologischen krankheiten
CR20230366A (es) Fracciones que prolongan la semivida y métodos de uso de estas
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE390144T1 (de) Behandlung von fibrosen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties